Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
512
datasets available to search
ShareScore release 0.9.0
Dataset results
512 results for “antidepressant”
Npbwr1 signaling mediates fast antidepressant action
GEO Series GSE271600. Mus musculus. 72 samples. Type: Expression profiling by high throughput sequencing.
RNA sequencing analysis of gene expression in the prefrontal cortex of mice treated with antidepressant drugs
GEO Series GSE168172. Mus musculus. 15 samples. Type: Expression profiling by high throughput sequencing.
Antidepressants affect gut microbiota and Ruminococcus flavefaciens is able to abolish their effects on depressive-like behavior
GEO Series GSE129359. Mus musculus. 24 samples. Type: Expression profiling by high throughput sequencing.
The Atypical Antidepressant Tianeptine Confers Neuroprotection against Oxygen-Glucose Deprivation
GEO Series GSE234798. Mus musculus. 16 samples. Type: Expression profiling by high throughput sequencing.
Myelin-Associated Oligodendrocytic Basic Protein-Dependent Myelin Repair Confers the Long-lasting Antidepressant Effect of Ketamine
GEO Series GSE214861. Mus musculus. 4 samples. Type: Other.
Multi-omics exploration demonstrated the antidepressant effects of chrysophanol on Diabetes-depression comorbidity rats via inflammatory, and neurodegenerative axes
GEO Series GSE296320. Rattus norvegicus. 9 samples. Type: Expression profiling by high throughput sequencing.
Sustained antidepressant effects of ketamine metabolite involve GABAergic inhibition-mediated molecular dynamics in aPVT glutamatergic neurons
GEO Series GSE233226. Mus musculus. 9 samples. Type: Expression profiling by high throughput sequencing.
MicroRNAs 146a/b-5p, 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes
GEO Series GSE97154. Homo sapiens. 516 samples. Type: Non-coding RNA profiling by high throughput sequencing.
Efficacy and safety evaluation of a new antidepressant drug agomelatine in the treatment of post-stroke depression: a single-center clinical study
<p><b><span>Objective: </span></b>To compare the effects of agomelatine and sertraline hydrochloride on the clinical efficacy, neurocytokine and monoamine transmitter metabolism in patients with post-stroke depression. </p> <p><b><span>Methods:</span></b> A total of 94 patients with post-stroke depression admitted to our hospital from July 2015 to September 2018 were randomly divided into a test group and a control group with 47 cases each. The experimental group was treated with agomelatine 25 mg/d orally, which was increased to 50 mg/d after 1 week, and the control group was treated with sertraline hydrochloride 50 mg/d. The two groups were treated continuously for 8 weeks. The clinical efficacy, the incidence of adverse reactions and the Hamilton Depression Scale (HAMD) before and after treatment, the National Institutes of Health Stroke Scale (NIHSS) score, BI index, and neurocytokines were compared between the two groups. Derived Neurotrophic Factor: BDNF; Nerve Growth Factor: NGF), Monoamine Transmitter Metabolism (5-Hydroxytryptamine: 5-HT; 5-Hydroxyindoleacetic acid: 5-HIAA; Norepinephrine: NE) changes.</p> <p><b><span>Results:</span></b> After treatment, the total effective rates of the experimental group and the control group were 82.97% (39 cases/47 cases) and 80.85% (38 cases and 47 cases), respectively, and the difference was not statistically significant (P>0.05). After treatment, there was no statistical difference between the test group and the control group in HAMD score, NIHSS score, and BI index (P>0.05). After treatment, there was no statistically significant difference between the test group and the control group in BDNF, NGF, 5-HT, 5-HIAA and NE (P>0.05). The incidence of adverse reactions in the experimental group and the control group were 17.02% and 19.14%, respectively, and the difference was not statistically significant (P>0.05).</p> <p><b><span>Conclusion: </span></b>Agomelatine and sertraline hydrochloride have the same clinical efficacy in the treatment of post-stroke depression, and the adverse reactions are relatively mild.</p>
Antidepressant mice behavioral video compression file
<p>Antidepressant mice behavioral video compression file(autonomous activity, forced swimming, tail suspension experiment)</p>
Precision Psychiatry for Depression: Immune Response and Affective Symptoms as Predictors of Response to Antidepressants
ClinicalTrials.gov study NCT06337539. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Antidepressant Mechanisms of Transcranial Magnetic Stimulation
ClinicalTrials.gov study NCT02466230. IPD Sharing: NO. Countries: 0. Publications: 0.
Transcranial Magnetic Stimulation Study of Cortical Excitability as Marker of Antidepressant Response: EXCIPSY Study
ClinicalTrials.gov study NCT03606850. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Physiologic Monitoring of Antidepressant Response
ClinicalTrials.gov study NCT00792168. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Evolution of Dark Ideas When Introducing or Switching an Antidepressant
ClinicalTrials.gov study NCT03327974. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Risperidone Augmentation Therapy in Patients Who Have Failed or Only Partially Responded to a Trial of Antidepressant
ClinicalTrials.gov study NCT00174577. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Combining Antidepressants and Attention Bias Modification in Depression
ClinicalTrials.gov study NCT05503966. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Study of Placebo Without Deception Versus Standard Antidepressant for Major Depressive Disorder
ClinicalTrials.gov study NCT01650740. IPD Sharing: Not stated. Countries: 1. Publications: 0.
First choIce Antidepressants: General Practitioner's Treatment Approach in the Czech Republic
ClinicalTrials.gov study NCT05291897. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Antidepressant Effect of Deep Brain Stimulation in Parkinson's Disease Patients
ClinicalTrials.gov study NCT00885222. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.